Respiratory Syncytial Virus Vaccines in Adults Who Are Not Pregnant or Immunocompromised: Rapid Practice Points From the American College of Physicians

Key Points

• The aim is to evaluate the potential benefits of a protein subunit RSV vaccine for older adults at increased risk for severe RSV infection.
• Target population aged 60 to 74 years
• Focus on non-pregnant and non-immunocompromised adults
• Analysis of vaccine efficacy
• Consideration of risk factors for severe RSV
• Adults aged 60 to 74 years may reduce risk for severe RSV through vaccination.
• The protein subunit vaccine is specifically suggested for those at increased risk for severe infection.